Merck & Co., Inc. (MRK)
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
- Ticker
- MRK
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $356.53B
- 52-week range
- $91.49 - $156.92
Valuation
- Share price
- $144.46 (close of Nov 16, 2026)
- P/E (TTM)
- 144.46x
- Price to book
- 7.93x
- Price to free cash flow
- 24.18x
- Enterprise value
- $400.75B
- Book value per share
- $18.21
Price performance
| Period | Change |
|---|---|
| 1 day | -2.23% |
| 5 days | -2.89% |
| 1 month | -1.02% |
| 3 months | +6.35% |
| 6 months | +29.70% |
| Year to date | +37.24% |
| 1 year | +55.47% |
| 3 years | +41.64% |
| 5 years | +71.75% |
| 10 years | +141.73% |
| All time | +9,698.09% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 1.08%
- Shares short
- 26.60M
- Days to cover
- 2.36
- Change since prior report
- -0.82%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed MRK trades
Gilbert Ray Cisneros · Julie Johnson · Maria Elvira Salazar · Marjorie Taylor Greene · Robert Bresnahan · Bruce Westerman · Byron Donalds · Jared Moskowitz · Jefferson Shreve · Josh Gottheimer · Lisa McClain · Ritchie Torres
Super investors holding MRK
Bill Nygren (Harris Associates LP) · Ken Griffin (Citadel) · Sarah Ketterer (Causeway Capital Management LLC) · Kahn Brothers (Kahn Brothers Group) · Prem Watsa (Fairfax Financial Holdings) · Dodge & Cox (Dodge & Cox Funds) · Mairs & Power (Mairs & Power Inc) · Christopher Bloomstran (Semper Augustus Investments Group LLC) · Ray Dalio (Bridgewater Associates) · Richard Pzena (Pzena Investment Management) · David Katz (Matrix Asset Advisors Inc) · Thomas Russo (Gardner Russo & Quinn LLC)
Profitability and growth
- Return on equity
- 34.66%
- Return on invested capital
- 19.24%*
- Return on assets
- 13.34%
- Return on capital employed
- 20.66%*
- Gross margin
- 74.80%
- Net margin
- 28.08%
- EBITDA margin
- 43.47%
- Revenue growth
- 1.31%
- Net income growth
- 6.64%
- Free cash flow growth
- -31.70%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 4.14%
- Current ratio
- 1.35x
- Net debt to EBITDA
- 3.14x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $65.01B
- Cost of revenue
- $16.38B
- Gross profit
- $48.63B
- EBITDA
- $28.26B
- Net income
- $18.25B
- Earnings per share
- $7.30
- Research and development
- $15.79B
- Interest expense
- $1.36B
- Shares outstanding
- 2.50B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $65.01B | $48.63B | $18.25B | $7.30 |
| 2024-12-31 | $64.17B | $48.98B | $17.12B | $6.76 |
| 2023-12-31 | $60.12B | $43.99B | $365.00M | $0.14 |
| 2022-12-31 | $59.28B | $41.87B | $14.52B | $5.73 |
| 2021-12-31 | $48.70B | $35.08B | $13.05B | $5.16 |
| 2020-12-31 | $41.52B | $27.90B | $7.07B | $2.79 |
| 2019-12-31 | $39.12B | $27.11B | $9.84B | $3.84 |
| 2018-12-31 | $42.29B | $28.79B | $6.22B | $2.34 |
| 2017-12-31 | $40.12B | $27.21B | $2.39B | $0.88 |
| 2016-12-31 | $39.81B | $25.78B | $3.92B | $1.42 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 74.80% | 28.08% | 34.66% | 19.24%* |
| 2024-12-31 | 76.32% | 26.68% | 36.91% | 22.05%* |
| 2023-12-31 | 73.17% | 0.61% | 0.97% | 2.10%* |
| 2022-12-31 | 70.63% | 24.49% | 31.52% | 20.18%* |
| 2021-12-31 | 72.02% | 26.79% | 34.11% | 18.06%* |
| 2020-12-31 | 67.20% | 17.02% | 27.82% | 9.10%* |
| 2019-12-31 | 69.29% | 25.16% | 37.86% | 12.18%* |
| 2018-12-31 | 68.06% | 14.71% | 23.14% | 13.40%* |
| 2017-12-31 | 67.82% | 5.97% | 6.93% | 6.17%* |
| 2016-12-31 | 64.75% | 9.85% | 9.73% | 7.11%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $14.56B | $46.75B |
| 2024-12-31 | $13.24B | $34.46B |
| 2023-12-31 | $6.84B | $33.68B |
| 2022-12-31 | $13.19B | $28.75B |
| 2021-12-31 | $8.10B | $30.69B |
| 2020-12-31 | $8.05B | $25.36B |
| 2019-12-31 | $10.43B | $22.74B |
| 2018-12-31 | $8.86B | $19.81B |
| 2017-12-31 | $8.49B | $21.35B |
| 2016-12-31 | $14.31B | $24.27B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $12.36B | $820.00M |
| 2024-12-31 | $18.10B | $761.00M |
| 2023-12-31 | $9.14B | $645.00M |
| 2022-12-31 | $14.71B | $541.00M |
| 2021-12-31 | $8.67B | $479.00M |
| 2020-12-31 | $5.82B | $441.00M |
| 2019-12-31 | $10.07B | $388.00M |
| 2018-12-31 | $8.31B | $348.00M |
| 2017-12-31 | $4.56B | $312.00M |
| 2016-12-31 | $8.76B | $300.00M |
Dividend history
- Most recent payment
- Sep 15, 2026
- Paid in the last twelve months
- $3.40
| Payment date | Dividend per share |
|---|---|
| 2026-09-15 | $0.85 |
| 2026-06-15 | $0.85 |
| 2026-03-16 | $0.85 |
| 2025-12-15 | $0.85 |
| 2025-09-15 | $0.81 |
| 2025-06-16 | $0.81 |
| 2025-03-17 | $0.81 |
| 2024-12-16 | $0.81 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-29 | Sep 2026 | $2.12 |
| 2026-08-04 | Jun 2026 | -$0.26 |
| 2026-04-30 | Mar 2026 | -$1.51 |
| 2026-02-03 | Dec 2025 | $2.03 |
| 2025-10-30 | Sep 2025 | $2.36 |
| 2025-07-29 | Jun 2025 | $2.01 |
| 2025-04-24 | Mar 2025 | $2.15 |
| 2025-02-04 | Dec 2024 | $1.69 |
Filings and sources
- Company website
- merck.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Novartis AG (NVS) · AbbVie Inc. (ABBV) · AstraZeneca plc (AZN) · Johnson & Johnson (JNJ) · Amgen Inc (AMGN) · Eli Lilly & Co (LLY) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades